Rhythm Pharmaceuticals Analysts Boost Their Forecasts Following Upbeat Q1 Results

All NewsMay 6, 2026

Rhythm Pharmaceuticals (NASDAQ: RYTM) reported better-than-expected earnings, with strong demand for IMCIVREE and potential launches in Europe and Japan.

Latest Ratings for RYTM

DateFirmActionFromTo Mar 2022Canaccord GenuityMaintainsBuy Mar 2022NeedhamMaintainsBuy Feb 2022NeedhamMaintainsBuy

View More Analyst Ratings for RYTM

View the Latest Analyst Ratings

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent